计算溶液所需的质量、体积或浓度。
AVE3085
有货
为什么选择此级别
Moligand™ 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.
In Vitro
Pre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level of p-eNOS Thr495 and nitrotyrosine. NO release in response to bradykinin is significantly reduced by ADMA and such reduction is restored by AVE3085. AVE3085 also prevents the elevation of O 2 .− and ONOO − levels in coronary arteries exposed to ADMA. AVE3085 (10 μM) markedly increases ACh-induced relaxations in SHR aortae without affecting those in WKY aortae, and also increases the eNOS expression in WKY aortae. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AVE3085 (10 mg/kg/day, p.o.) treatment prevents the increases in the left ventricular weight, left ventricular weight/body weight ratio, mean myocyte diameter, and the expression of the hypertrophic markers ANP and β-MHC compared to the vehicle-treated mice. AVE 3085 treatment also attenuates the collagen volume fraction levels compared to the vehicle-treated mice. In the AVE3085-treated mice, the EFs, FSs, mitral E velocity, E/A ratio and LVDds are significantly improved compared to the vehicle-treated mice. AVE 3085 treatment attenuates the increase in the expression of Smad2 mRNA. Furthermore, the levels of the eNOS protein expression are significantly up-regulated in the AVE3085 group than in the vehicle-treated AB group . AVE3085 (10 mg/kg, p.o.) significantly improves ACh-induced endothelium-dependent relaxations in the aortae of SHRs, and reduces systolic blood pressure in SHRs. AVE3085 treatment for 4 weeks increases levels of p-eNOS and eNOS in SHR aortae without affecting levels of eNOS and p-eNOS in WKY aortae. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
规格
规格或纯度
Moligand™,10mM in DMSO
英文名称
AVE3085
生化机理
AVE3085 是一种强效的内皮一氧化氮合酶增强剂，用于治疗心血管疾病。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
激活剂
名称和识别符
分子类型
小分子
Isomeric SMILES
C1C(CC2=CC=CC=C21)NC(=O)C3=CC4=C(C=C3)OC(O4)(F)F
关联CAS
PubChem CID
MeSH Entry Terms
2,2-difluorobenzo(1,3)dioxole-5-carboxylic acid indan-2-ylamide;AVE 3085;AVE-3085;AVE3085
分子量
317.29
技术文档
高级数据
安全和危险性（GHS）
质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 SSE:688179 保留所有权利。
危险品化学品经营许可证（带存储）